|Bid||6.43 x 900|
|Ask||6.55 x 1200|
|Day's Range||6.40 - 6.79|
|52 Week Range||3.00 - 17.19|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.11|
Autolus Therapeutics (NASDAQ:AUTL) announces its next round of earnings this Thursday, March 04. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement. What Are Earnings, Net Income, And Earnings Per Share? Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding. Earnings And Revenue Autolus Therapeutics's per-share loss will be near $0.77 on sales of $340.00 thousand, according to Wall Street analysts. In the same quarter last year, Autolus Therapeutics reported a loss per share of $0.93 on sales of $309.00 thousand. What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter? Wall Street analysts who study this company will publish analyst estimates of revenue and EPS. The averages of all analyst EPS and revenue estimates are called the "consensus estimates"; these consensus estimates can have a significant effect on a company's performance during an earnings release. When a company posts earnings or revenue above or below a consensus estimate, it has posted an "earnings surprise", which can really move a stock depending on the difference between actual and estimated values. View more earnings on AUTL If the company were to report earnings in line when it publishes results Thursday, earnings would be up 17.2%. Revenue would be up 10.03% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past: Quarter Q3 2020 Q2 2020 Q1 2020 Q4 2020 EPS Estimate -0.71 -0.71 -0.74 -0.74 EPS Actual -0.72 -0.62 -0.60 -0.93 Revenue Estimate 300.00 K 440.00 K 600.00 K 520.00 K Revenue Actual 680.00 K 293.00 K 338.00 K 309.00 K Stock Performance Shares of Autolus Therapeutics were trading at $6.8 as of March 02. Over the last 52-week period, shares are down 25.54%. Given that these returns are generally negative, long-term shareholders are probably unhappy going into this earnings release. Do not be surprised to see the stock move on comments made during its conference call. Autolus Therapeutics is scheduled to hold the call at 08:30:00 ET and can be accessed here. See more from BenzingaClick here for options trades from BenzingaFirst Eagle Alternative's Earnings OutlookPreview: Purple Innovation's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Autolus Therapeutics PLC Sponsored ADR (AUTL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021. The company will also host one-on-one meetings with attendees. A live audio webcast of the presentation will be available on-demand on the investor relations section of Autolus’ website at events starting March 9 at 7.00 a.m. EST. An archived replay will be available on the company’s website for a period of 90 days after the conference. About Autolus Therapeutics plc Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com. Contact: Lucinda Crabtree, PhDVice President, Investor Relations and Corporate Communications+44 (0) 7587 372 firstname.lastname@example.org Julia Wilson+44 (0) 7818 email@example.com Susan A. NoonanS.A. Noonan Communicationsfirstname.lastname@example.org